Vigil Neuroscience (VIGL)
(Delayed Data from NSDQ)
$4.40 USD
+0.21 (5.01%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $4.26 -0.14 (-3.18%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VIGL 4.40 +0.21(5.01%)
Will VIGL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VIGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIGL
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy
VIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know
How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133%
Wall Street Analysts Believe Vigil Neuroscience, Inc. (VIGL) Could Rally 167%: Here's is How to Trade
Other News for VIGL
Vigil Neuroscience price target raised by $1 at Wedbush, here's why
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Vigil Neuroscience Inc (VIGL) and Cooper Co (COO)
Vigil Neuroscience Inc.: A Cautious Sell Amid Development Uncertainties and Potential Conflict of Interest
Buy Rating Affirmed for Vigil Neuroscience Amid Promising Alzheimer’s Treatment Developments
Sanofi investing $400M in Vigil Neuroscience, says Guggenheim